Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

FDA acknowledges that AstraZeneca’s Imfinzi® (Durvalumab) Phase III Trial Met Primary Endpoint

Jul 25, 2024

On 25 July 2024, AstraZeneca announced the FDA’s Oncologic Drugs Advisory Committee acknowledged that its Imfinzi® (durvalumab) met the primary endpoint of event-free survival (EFS) in the treatment of resectable non-small cell lung cancer (NSCLC), based on Phase III results.  The FDA accepted the supplemental Biologics License Application (sBLA) for Imfinzi® in this indication in September 2023.

Earlier this month, AstraZeneca announced that its Imfinzi® and Lynparza® (olaparib) combination had been recommended for approval by the EMA’s Committee for Medicinal Products for Human Use (CHMP) for certain patients with primary advanced or recurrent endometrial cancer.